Navigation Links
Extensive Scientific Data Supports the Clinical Validity of Pharmacogenomic Testing for Predicting Patient Response to Psychiatric Medications

MASON, Ohio, Oct. 28, 2013 /PRNewswire/ -- Assurex Health, a leading personalized medicine company, announced today that the International Review of Psychiatry published an extensive review that validates the clinical use of pharmacogenomic testing to help predict patient response to psychiatric medications and improve treatment outcomes. The paper provides substantial evidence that psychiatric pharmacogenomic testing has proven clinical value in predicting how individual patients will tolerate and respond to specific psychiatric medications. These findings refute results of a previous assessment of pharmacogenomic testing conducted in 2007 by the Evaluation of Genomic Applications in Practice and Prevention initiative (EGAPP) which concluded that there was insufficient evidence to determine the value of pharmacogenomic testing for adults beginning treatment with SSRI antidepressants.

(Logo: )

The current article titled "Clinical Validity of Cytochrome P450 Metabolism and Serotonin Gene Variants in Psychiatric Pharmacotherapy"* reviewed published data collected since 2007 examining how DNA sequence variations between individuals can affect their metabolism and response to medications.  The preponderance of evidence from these studies supports the validity of analyzing patients' genetic profile to predict the metabolism, safety, and therapeutic efficacy of psychotropic medications commonly used for the treatment of depression, schizophrenia, and bipolar disorder.    

"A review of 294 scientific studies published since the EGAPP report clearly demonstrates the clinical validity of multiple genes in predicting patient responses to antidepressant medications.  This assessment is further supported by multiple clinical trials demonstrating that understanding variations in these same genes leads to better treatment decisions and better patient outcomes," said C. Anthony Altar, Ph.D., Chief Science Officer of Assurex Health and lead author.   

"The review of these clinical and scientific data clearly reinforces the benefits of pharmacogenomic testing in aiding medication selection and augmenting patient responses to antidepressant and antipsychotic medications. Use of pharmacogenomic testing leads to earlier identification of optimal treatment protocols for individual patients," said Assurex Health CEO James S. Burns.  "The question is no longer whether pharmacogenomic testing is ready for routine clinical use; rather, how to make it available earlier in the course of patient treatment to improve patient outcomes."   
About the Publication   

The authors conducted a systematic literature review to assess whether pharmacokinetic (PK) or pharmacodynamic (PD) responses to 26 commonly prescribed antidepressant and antipsychotic medications, including efficacy or side effects, are associated with nucleotide polymorphisms in eight commonly studied genes in psychiatric pharmacotherapy.  Of the 294 publications reviewed, a majority showed significant associations between polymorphisms and patient response to psychotropic medications.  In many cases, a lack of association was traced to inappropriate comparisons between a medication and the gene being evaluated.  The findings showed that combinatorial pharmacogenomic tests can help predict genetically appropriate medication choices and improve patient outcomes.      

*Authors of the article are: C. Anthony Altar, Ph.D., John Hornberger, M.D., M.S., Ashwini Shewade, M.S., M.Sc., Victor Cruz, B.S., Jill Garrison, M.S. and David Mrazek, M.D., FRC-Psych.  The review has been dedicated to the memory of David A. Mrazek, a pioneer in the theory and clinical application of psychiatric pharmacogenomics.   

About Assurex Health  

Assurex Health is a personalized medicine company that specializes in pharmacogenomics and is dedicated to helping physicians determine the right medication for individual patients suffering from neuropsychiatric and other disorders. The company was founded to commercialize industry-leading personalized medicine technology for neuropsychiatric disorders. Assurex Health has licensed technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center. Mayo Clinic has a financial interest in the technology referenced in this news release.   

For more information about Assurex Health, please visit   

About GeneSight   

GeneSight is a laboratory-developed pharmacogenomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSight report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, manufacturers' FDA approved drug labels, peer reviewed scientific and clinical publications, and proven drug pharmacology.  Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can provide information to help a physician make personalized drug treatment choices for each patient.  

Registered trademarks are the property of their respective owners.   

SOURCE Assurex Health
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Recognizes ASCEND HiT for Providing Extensive Value Enhancement to Industry Partners and Providers through its Best-of-Breed Products
2. Abilities Expo -- The Nations Leading Expo for People with Disabilities -- to Feature Push Girls star, Auti Angel, along with an extensive Line Up of New Products, Services and Technology at Reliant Center, August 2-4
3. Leading Home Medical Supplies Retailer Med Supply Shop Spotlights Its Extensive Inventory of Power Wheelchairs
4. For Treatment of Extensive-Disease Small-Cell Lung Cancer (ED-SCLC), No Emerging Therapy is Likely to Replace Etoposide/Carboplatin as the Standard of Care Before 2022
5. Home Medical Supply Store Showcases Its Extensive Range of Medical Products
6. ALCOR Scientific Inc. Welcomes New COO
7. Boston Scientific Receives Prestigious 2013 Prix Galien Award For Best Medical Technology
8. Osteo Science Foundation to Support Scientific and Clinical Research in Oral and Maxillofacial Surgery
9. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
10. Heart Failure Society of America 17th Annual Scientific Meeting To Focus On New Developments In Heart Failure Cause, Care And Treatment
11. New York Genome Center Launches Groundbreaking Consortium to Accelerate Scientific and Clinical Discoveries
Post Your Comments:
(Date:12/1/2015)... 1, 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... pain, announced today that the company will present at the ... 1-3 at the Luxe Sunset Boulevard Hotel in ... of Relmada Therapeutics, will present on Thursday, December 3, at ... . Please register at least 10 minutes prior to ...
(Date:12/1/2015)... DIEGO , Dec. 1, 2015   MabVax ... drug development company, announces it has filed an Investigational ... Drug Administration (FDA) for the Company,s lead fully human ... to FDA acceptance, MabVax plans to initiate the Phase ... --> --> The planned Phase ...
(Date:12/1/2015)... 1, 2015   Craneware, Inc ., the ... today announced the company will showcase a new ... ® solution at the American Society for ... . The new features are focused on simplifying ... and managing enterprise-wide pharmacy charges to ensure compliance ...
Breaking Medicine Technology:
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... solutions for the care management and population health arenas, is pleased to announce ... and cost containment services, has successfully implemented the ACUITY Complete Care™ Management to ...
(Date:12/1/2015)... Atlanta, GA (PRWEB) , ... December 01, 2015 ... ... manufacturing, supports SACC-GA and SACC-USA through membership and leadership since 2008. ... and Chair for SACC-USA . Gary has spent a significant amount of ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Luxury’s Angeleno Magazine as a Modern Man for 2015. , Angeleno Magazine ... in the United States. Established in 1994, Modern Luxury includes more than 50 ...
Breaking Medicine News(10 mins):